Precigen turns profitable as Papzimeos quarterly revenue reaches $72.9m

Precigen has reported a profitable third quarter, with its recurrent respiratory papillomatosis therapy Papzimeos (zopapogene imadenovec-drba) generating $72.9m in net revenue. The company announced the figures on 4 November and described the product's sales growth as 37%.

Net income for the three months came to $35.8m, and the company said cash flow was positive. The summary of the release does not break down costs or give guidance, and it does not specify the period against which the 37% increase is measured, so the underlying trajectory is hard to judge from the available material.

Papzimeos is indicated for adults with recurrent respiratory papillomatosis. Precigen noted that a permanent HCPCS J-code, J3404, has been in effect since April 2026. Such a code gives the product a standard billing identifier in the US.

On the regulatory front, the FDA has granted Platform Technology Designation to the company's AdenoVerse platform. As general context, the agency's designation scheme is meant to let it draw on data from a designated platform when reviewing later products built on the same technology, though any benefit depends on the details of each application.

Separately, a marketing authorisation application for Papzimeos is being reviewed by the European Medicines Agency. No timeline for an opinion was available in the material reviewed.